The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.
Their core focus, at the moment, is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management, and even weight management.
The “QTY Code” Breakthrough Technology
Avalon recently announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer.
The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy.
The “QTY Code” breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D. MIT’s Media Lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development.
A team of scientists led by Dr. Zhang applied the QTY code to the 14 glucose transport membrane proteins that transport sugar to cells. They used Google’s AlphaFold2, a DeepMind AI program, which can accurately and quickly predict how proteins fold. Dr. Zhang and his team used the QTY code with the open-source AlphaFold2 to predict the structures of these proteins in both their natural hydrophobic shapes and their QTY-code altered water-soluble shapes.
Click here for more QTY code info.
Avalon Files To Protect “IP”
Recently, Avalon jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.
The new intellectual property covers three core patent families:
Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.
Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.
Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.
Find more patent info here.
And right now, multiple potential catalysts could fuel a vertical chart move in the near term for ALBT. They are:
No. 1 ALBT Potential Catalyst - Signing Of Game-Changing, Transformative Definitive Agreement For Acquisition
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25Mn
FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company"), a leading global developer of innovative cell-based technologies and therapeutics, today announced that it has signed a definitive acquisition agreement (the "Acquisition Agreement") to acquire a 60% interest in Laboratory Services MSO, LLC, a premier reference laboratory. In connection with the transaction, and to reflect the expanded focus on lab testing and services, Avalon will be changing its ticker symbol from "AVCO" to "ALBT." ...
Headquartered in Costa Mesa California, Laboratory Services provides a broad portfolio of diagnostic tests including dr-ug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. Laboratory Services has developed a premier reputation for customer service and fast turnaround times in the industry. Laboratory Services has completed over 450,000 tests since inception, operates with 2021 unaudited annual revenue in excess of $25Mn and has two locations in California.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "This is a transformative acquisition for Avalon as it brings significant revenue and positive cash flow and is expected to be highly accretive to earnings while adding strong clinical synergies to the existing Avalon portfolio. Laboratory Services has an impressive history of growth and is an established leader within the highly fragmented market for lab testing and services. Laboratory Services' diagnostic business is highly synergistic with our existing precision companion diagnostic business and cellular technology platforms."
"We are delighted to welcome Sarah Cox, Co-founder and CEO of Laboratory Services, and the entire Laboratory Services team to Avalon. Sarah and her team have a proven track record and tremendous reputation within the industry," concluded Dr. Jin.
Sarah Cox, Co-Founder and CEO of Laboratory Services, further noted, "We could not be more excited to join forces with Avalon, as we share a common culture and commitment to putting the patient's needs first. We have become a one stop shop for most clinical testing and each client is provided white glove treatment. We believe that the combination of our established infrastructure with Avalon's resources, as well as cutting edge diagnostic and immune-therapy platform, is expected to establish Avalon as a formidable force in this rapidly growing industry."
Read the full article here.
No. 2 ALBT Potential Catalyst - A Low Float Could Allow For Daily Volatility
According to the Yahoo Finance website, ALBT has a low float.
The website reports this profile to haven approximately 32.21Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news before the end of the year help provide a near term spark?
No. 3 ALBT Potential Catalyst - An Explosive Chart History Of Massive Short Term Moves
To put it simply, ALBT's has a chart history full of explosive short term moves.
Here's a quick list of times where ALBT made a wild move:
#1. From a July 21st low of $.4225, ALBT made a move to a high of $.8050 two weeks late on August 4th. Boom. 90% just like that.
#2. That was followed up soon after by a move from September 26th low of $.42 to a September 30th high of $.79. That's 88% in less than a week.
#3. ALBT blazed a path from a low of $.38 on November 1st to a high of $.595 on November 4th. Wow. 56% in a blink.
#4. Most recently, ALBT rocketed from a December 9th low of $.30 to a December 13th high of $.4866. That's 62% in a handful of days.
Explosive. Short term. Mover.
No. 4 ALBT Potential Catalyst - Company Receives Notice Of Allowance Related To QTY Protein Platform
Avalon GloboCare Receives Allowance for Joint U.S. Patent
Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose Transporters
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp., a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company’s intellectual property portfolio featuring its QTY protein code technology.
The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.
The Company also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This patent application was also jointly filed with Dr. Shuguang Zhang of MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.
The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.
Avalon’s proprietary AVA-Trap™ technology utilizes the artificial intelligence (AI) enhanced QTY Code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as CV-19 and cancer metastasis.
“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”
“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,” said Dr. Jin.
Read the full article here.
ALBT Recap: These Potential Catalysts Could Fuel A Vertical Move For This Nasdaq Profile
No. 1 - Signing Of Game-Changing, Transformative Definitive Agreement For Acquisition
No. 2 - A Low Float Could Allow For Daily Volatility
No. 3 - An Explosive Chart History Of Massive Short Term Moves
No. 4 - Company Receives Notice Of Allowance Related To QTY Protein Platform
Coverage is officially reinitiated on ALBT. When time permits, do this: